US 2019/0161744 A1 · Compositions Comprising Polypeptides having Galactanase Activity and Polypeptides having Beta-Galactosidase Activity

Abstract

The present invention relates to compositions comprising polypeptides having galactanase activity and polypeptides having beta-galactosidase activity for use in e.g. animal feed. The present invention further relates to polypeptides having beta-galactosidase activity, polypeptides having galactanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Claims29

Dependent claims

A composition comprising one or more GH53 polypeptides having galactanase activity and one or more GH35 polypeptides having beta-galactosidase activity.

An isolated polypeptide having galactanase activity, selected from the group consisting of:

(a) a polypeptide having at least 82% sequence identity to the polypeptide of SEQ ID NO:
3;
(b) a polypeptide having at least 83% sequence identity to the polypeptide of SEQ ID NO:
7;
(c) a polypeptide having at least 99.0% sequence identity to the polypeptide of SEQ ID NO:
11;
(d) a polypeptide having at least 96.4% sequence identity to the polypeptide of SEQ ID NO:
15;
(e) a polypeptide having at least 84% sequence identity to the polypeptide of SEQ ID NO:
19;
(f) a polypeptide having at least 96.4% sequence identity to the polypeptide of SEQ ID NO:
23;
(g) a polypeptide having at least 86% sequence identity to the polypeptide of SEQ ID NO:
27;
(h) a polypeptide having at least 99.3% sequence identity to the polypeptide of SEQ ID NO:
31;
(i) a polypeptide having at least 99.3% sequence identity to the polypeptide of SEQ ID NO:
35;
(i) a polypeptide having at least 83% sequence identity to the polypeptide of SEQ ID NO:
39;
(k) a polypeptide encoded by a polynucleotide having at least 82% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
1;
(l) a polypeptide encoded by a polynucleotide having at least 83% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
5;
(m) a polypeptide encoded by a polynucleotide having at least 99.0% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
9;
(n) a polypeptide encoded by a polynucleotide having at least 96.4% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
13;
(o) a polypeptide encoded by a polynucleotide having at least 84% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
17;
(p) a polypeptide encoded by a polynucleotide having at least 96.4% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
21;
(q) a polypeptide encoded by a polynucleotide having at least 86% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
25;
(r) a polypeptide encoded by a polynucleotide having at least 99.3% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
29;
(s) a polypeptide encoded by a polynucleotide having at least 99.3% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
33;
(t) a polypeptide encoded by a polynucleotide having at least 83% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
37;
(u) a variant of SEQ ID NO:
3, SEQ ID NO:
7, SEQ ID NO:
19, SEQ ID NO:
27 or SEQ ID NO:
39 wherein the variant has galactanase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions;
(v) a variant of SEQ ID NO:
11 wherein the variant has galactanase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2 or 3 positions;
(w) a variant of SEQ ID NO:
15 or SEQ ID NO:
23 wherein the variant has galactanase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 positions;
(x) a variant of SEQ ID NO:
31 or SEQ ID NO:
35 wherein the variant has galactanase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1 or 2 positions;
(y) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) or (x) and a N-terminal and/or C-terminal His-tag and/or HQ-tag;
and
(z) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) or (x) and a N-terminal and/or C-terminal extension of up to 10 amino acids, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids;
and
(aa) a fragment of the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) or (x) having galactanase activity and having at least 90% of the length of the mature polypeptide.

56 more elements

An isolated polypeptide having beta-galactosidase activity, selected from the group consisting of:

(a) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:
43;
(b) a polypeptide having at least 83% sequence identity to the polypeptide of SEQ ID NO:
46;
(c) a polypeptide having at least 96.4% sequence identity to the polypeptide of SEQ ID NO:
49;
(d) a polypeptide having at least 92% sequence identity to the polypeptide of SEQ ID NO:
52;
(e) a polypeptide having at least 99.7% sequence identity to the polypeptide of SEQ ID NO:
55;
(f) a polypeptide having at least 93%, sequence identity to the polypeptide of SEQ ID NO:
58;
(g) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO:
61;
(h) a polypeptide having at least 95.5% sequence identity to the polypeptide of SEQ ID NO:
70;
(i) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:
73;
(j) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:
76;
(k) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
41;
(l) a polypeptide encoded by a polynucleotide having at least 83% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
44;
(m) a polypeptide encoded by a polynucleotide having at least 96.4% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
47;
(n) a polypeptide encoded by a polynucleotide having at least 92% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
50;
(o) a polypeptide encoded by a polynucleotide having at least 99.7% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
53;
(p) a polypeptide encoded by a polynucleotide having at least 93% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
56;
(q) a polypeptide encoded by a polynucleotide having at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
59;
(r) a polypeptide encoded by a polynucleotide having at least 95.5% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
70;
(s) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
73;
(t) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:
76;
(u) a variant of SEQ ID NO:
43, SEQ ID NO:
46, SEQ ID NO:
52, SEQ ID NO:
58, SEQ ID NO:
61, SEQ ID NO:
73 or SEQ ID NO:
76 wherein the variant has beta-galactosidase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions;
(v) a variant of SEQ ID NO:
49 wherein the variant has beta-galactosidase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 or 38 positions;
(w) a variant of SEQ ID NO:
55 wherein the variant has beta-galactosidase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2 or 3 positions;
(x) a variant of SEQ ID NO:
70 wherein the variant has beta-galactosidase activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 43 positions;
(y) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) or (x) and a N-terminal and/or C-terminal His-tag and/or HQ-tag;
and
(z) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) or (x) and a N-terminal and/or C-terminal extension of up to 10 amino acids, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids;
and
(aa) a fragment of the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) or (x) having beta-galactosidase activity and having at least 90% of the length of the mature polypeptide.

56 more elements

Dependencies are inferred from the claim text.

Compositions Comprising Polypeptides having Galactanase Activity and Polypeptides having Beta-Galactosidase Activity

Life of this patent

Compositions Comprising Polypeptides having Galactanase Activity and Polypeptides having Beta-Galactosidase Activity

Life of this patent

Abstract

Claims29